IUPAC: 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one · C21H23ClFNO2 · MW 375.87 g/mol · CAS 52-86-8 · ATC N05AD01
Haloperidol (Haldol). The prototypical high-potency butyrophenone typical antipsychotic — Janssen's R-1625, approved 1967. A near-pure dopamine D2 antagonist/inverse agonist: minimal anticholinergic or sedating "atypical" polypharmacology, maximal on-target D2 blockade. The reference compound for the dopamine hypothesis of psychosis — and the reference compound for extrapyramidal harm. Trade/context names: Haldol, Serenace, Haldol Decanoate (long-acting depot).
Haloperidol is a competitive antagonist / inverse agonist at the dopamine D2 receptor (D2-like family: D2, D3, D4), binding the orthosteric aminergic pocket with sub-nanomolar-to-nanomolar affinity (Ki ≈ 1.4 nM at human D2). D2 is a Gi/o-coupled GPCR: its normal job is to lower cAMP and gate downstream signaling to dopamine tone. By occupying that pocket, haloperidol removes dopaminergic drive — de-repressing adenylyl cyclase, restoring cAMP/PKA/DARPP-32 signaling, and silencing the D2-mediated inhibition of neuronal firing. This is the pharmacological inverse of cocaine: instead of flooding synapses with dopamine, haloperidol clamps the receptor that reads it.
Antipsychotic efficacy tracks tightly with D2 occupancy. PET studies place the therapeutic window at roughly 65–78% striatal D2 occupancy; extrapyramidal side effects (EPS) climb steeply above ~80%, and prolactin elevation above ~72%. Because haloperidol is so potent and so selective for D2, it pushes into the EPS zone at clinically ordinary doses — it has essentially no built-in anticholinergic or 5-HT2A-dominant buffer to soften striatal blockade, which is exactly what distinguishes a "typical" from an "atypical."
Haloperidol's protonated piperidine amine forms the conserved salt bridge to Asp3.32 (D114); the chlorophenyl and fluorophenyl arms fill the hydrophobic subpockets. It stabilizes the inactive receptor state, blocking Gi coupling (Ki ≈ 1.4 nM).
Nearly equipotent at D3 (Ki ≈ 6 nM), the D2-like autoreceptor enriched in limbic striatum. Contributes to antipsychotic action and to blunted reward/motivation seen with chronic dosing.
Haloperidol is a classic high-affinity σ1 ligand (Ki ≈ 3 nM) — historically it defined the "haloperidol-sensitive" sigma site. Modulates ER-mitochondrial Ca²⁺ and NMDA tone; pharmacological role in humans still debated.
Modest 5-HT2A antagonism (Ki ≈ 120 nM), ~85× weaker than D2. Too weak to confer an atypical 5-HT2A:D2 ratio — the mechanistic reason haloperidol carries the high EPS burden of a typical agent.
Potent block of the cardiac rapid delayed-rectifier K⁺ current IKr (hERG IC50 ≈ 27 nM). Delays ventricular repolarization → dose-dependent QTc prolongation and torsades-de-pointes risk, especially IV.
α1A antagonism (Ki ≈ 11 nM) causes orthostatic hypotension and reflex tachycardia. Negligible H1 and muscarinic affinity — why haloperidol is far less sedating and less anticholinergic than low-potency phenothiazines.
The signature of a high-potency typical: one dominant target, dose-limited by that same target in the wrong brain region. The dopamine circuit haloperidol needs to quiet (mesolimbic) and the one it must not quiet (nigrostriatal) share the same receptor. There is no molecular way for the drug to tell them apart — the selectivity problem is anatomical, not chemical.
Haloperidol is highly lipophilic (logP ≈ 4.4) and extensively tissue-distributed (Vd ≈ 8–30 L/kg — brain and fat concentrations far exceed plasma). Oral bioavailability is ~60–70% due to first-pass metabolism; IM and IV bypass it. The elimination half-life is long (~14–26 h oral) and highly variable between individuals — a major reason serum levels track dose so poorly. The decanoate ester depot is hydrolyzed slowly in muscle, giving an apparent half-life of ~3 weeks and monthly dosing.
Metabolism cascade: three parallel hepatic routes. Glucuronidation is quantitatively dominant; ketone reduction gives a weakly active metabolite that can be re-oxidized back to parent; and oxidative N-dealkylation via CYP3A4 (with CYP2D6) can also generate a pyridinium species.
Reduced haloperidol (ketone → secondary alcohol, via carbonyl reductase) retains only a fraction of D2 affinity but forms a large, slowly interconverting reservoir — it back-oxidizes to active parent, buffering plasma levels. HPP⁺ (a haloperidol pyridinium metabolite, marked ★) is structurally analogous to MPP⁺, the neurotoxin generated from MPTP that kills nigral dopamine neurons; whether HPP⁺ contributes to long-term motor toxicity in humans is an open, biologically plausible question, not a settled fact.
CYP3A4 is the pivotal interaction node. Strong 3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) and 2D6 inhibitors raise haloperidol exposure and QT risk; strong inducers (carbamazepine, rifampin, smoking-induced pathways) can drop levels and precipitate relapse. Haloperidol is also a substrate/weak modulator that compounds QT risk when stacked with other IKr blockers.
Haloperidol's entire clinical profile — therapeutic and adverse — is the story of blocking D2 in four anatomically distinct dopamine tracts simultaneously. The drug cannot choose; occupancy is roughly uniform. What differs is what each circuit does when its dopaminergic tone is removed.
VTA → nucleus accumbens / ventral striatum. Hyperdopaminergia here is the leading correlate of positive psychotic symptoms (hallucinations, delusions). D2 blockade dampens aberrant salience assignment. This is the therapeutic pathway — and the only one where blockade is wanted. Onset of behavioral calming is fast; full antipsychotic response takes 1–3 weeks (depolarization block of dopamine neurons).
SNc → dorsal striatum, the motor-control loop. Blocking D2 here mimics Parkinson's disease: acute dystonia (hours–days), drug-induced parkinsonism and akathisia (days–weeks). With chronic blockade, striatal D2 receptors up-regulate and become supersensitive → tardive dyskinesia, involuntary orofacial/limb movements that can be irreversible. Haloperidol carries one of the highest TD risks of any antipsychotic precisely because its D2 blockade is so pure and so complete.
Hypothalamus → anterior pituitary. Dopamine is the tonic brake on prolactin release (via lactotroph D2). Remove the brake and prolactin surges: galactorrhea, gynecomastia, amenorrhea, sexual dysfunction, and — over years — reduced bone density. Haloperidol is a robust, dose-dependent prolactin elevator because the pituitary sits outside the blood–brain barrier and sees high drug concentrations.
VTA → prefrontal cortex. This pathway is thought to be hypodopaminergic in schizophrenia, and is already driving negative symptoms (avolition, flat affect) and cognitive deficits. Non-selective D2 blockade here can worsen them — the reason haloperidol does little for negative symptoms and can produce a subjective "neuroleptic dysphoria" and anhedonia. Atypicals partly spare this pathway via 5-HT2A antagonism; haloperidol does not.
Haloperidol remains clinically indispensable: rapid tranquilization of acute agitation, schizophrenia, acute mania, Tourette syndrome and severe tics, delirium (used cautiously), and Huntington's chorea. Its problem was never efficacy at D2 — it was that D2 is everywhere dopamine is.
Four syndromes account for most of haloperidol's serious harm, and each maps cleanly onto a mechanism already described. None is idiosyncratic magic — they are the on-target and off-target pharmacology of the molecule made clinical.
Extrapyramidal symptoms (EPS) are a spectrum: acute dystonia (sustained muscle spasms — neck, eyes, jaw, rarely larynx; a medical emergency, treated with IM anticholinergics like benztropine or diphenhydramine), akathisia (an agonizing motor restlessness that is frequently mistaken for worsening psychosis and mis-treated by raising the dose), and drug-induced parkinsonism. Tardive dyskinesia emerges after months–years and may persist after the drug is stopped; VMAT2 inhibitors (valbenazine, deutetrabenazine) are the modern treatment.
Neuroleptic malignant syndrome (NMS) is the feared idiosyncratic reaction: a life-threatening dysautonomic crisis from central D2 hypofunction — hyperthermia, lead-pipe rigidity, altered mental status, and autonomic instability, with grossly elevated creatine kinase from muscle breakdown (rhabdomyolysis → acute kidney injury). It is more likely with high-potency agents like haloperidol, rapid dose escalation, and parenteral use. NMS is a stop-the-drug, cool-the-patient, call-ICU emergency (supportive care ± dantrolene, bromocriptine); mortality is significant if missed. QT prolongation from hERG blockade is dose-dependent and worst with IV administration — IV haloperidol carries an FDA warning for torsades and requires ECG/electrolyte monitoring.
Haloperidol is a moderately flexible ligand — the butyrophenone spacer contributes
six rotatable bonds linking a 4-fluorophenyl ketone to the 4-(4-chlorophenyl)-4-hydroxypiperidine
headgroup. Unlike cocaine's pre-organized tropane cage, haloperidol pays a real
conformational entropy penalty (ΔS_conf < 0) on binding: the flexible
C4 chain must fold into a single bound rotamer, and the protonated piperidine nitrogen must dock
precisely onto Asp3.32 (D114) to satisfy the conserved aminergic salt bridge. That enthalpic anchor
is what pays for freezing the chain.
The D2 orthosteric pocket (resolved in PDB 6LUQ, the haloperidol-bound
receptor) is a deep, largely hydrophobic aminergic cavity flanked by the extracellular vestibule.
In its apo state the pocket samples multiple side-chain conformers — high H_pocket
Shannon entropy. Haloperidol's two halogenated aromatic arms clamp the transmembrane bundle into the
inactive conformation, and the pocket's conformational ensemble collapses onto a single
state. This entropy collapse is the thermodynamic fingerprint of a high-affinity antagonist
locking a GPCR — the same signature FlexAID∆S resolves for competitive inhibitors that trap flexible
proteins, distinct from agonists that permit residual active-state breathing.
Observed human D2 affinity Ki ≈ 1.4 nM corresponds to
ΔGbind = −RT·ln(Ka) ≈ −12.1 kcal/mol at 310 K. A tENCoM-informed
FlexAID∆S decomposition would attribute this to a strong enthalpic core (salt bridge + halogen/aromatic
contacts) partly offset by the −TΔS_conf cost of the folded butyrophenone chain — a
rigidification signature at the receptor that, on the tissue scale, is mirrored by the striatal
rigidity the drug is infamous for.
Haloperidol is a prescription neuroleptic, not a recreational or PRN "knockout" agent. Most harm is mechanistic and predictable — and much of it is preventable with the right monitoring and a low index of suspicion for the emergencies below.
| Target | Affinity | Rel. | Action |
|---|---|---|---|
|
D2
Dopamine D2 receptor (DRD2)
|
Ki ≈ 1.4 nM
primary target
|
Antagonist | |
|
σ1
Sigma-1 receptor
|
Ki ≈ 3 nM
|
Ligand | |
|
D3
Dopamine D3 receptor (DRD3)
|
Ki ≈ 6 nM
|
Antagonist | |
|
α1A
Alpha-1A adrenergic receptor
|
Ki ≈ 11 nM
|
Antagonist | |
|
hERG
Kv11.1 / KCNH2 channel
|
IC50 ≈ 27 nM
QT liability
|
Blocker | |
|
5-HT2A
Serotonin 2A receptor
|
Ki ≈ 120 nM
|
Antagonist |